For instance, the Phase 1/2 ALSpire trial (NCT04494256) assessed BIIB105, an investigational ASO designed to reduce ataxin-2 protein levels and mitigate TDP-43 protein aggregation in Amyotrophic Lateral Sclerosis (ALS) [13,14]. Here, ATXN2 is linked to amyotrophic lateral sclerosis.